IP Library Granted Patent US 7,977,322
Granted Patent B2
US 7,977,322 · App. 11/202,278 · Granted Jul 12, 2011

Modulators of ATP-binding cassette transporters

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,977,322
App. No.
11/202,278
Granted
Jul 12, 2011
Kind
B2
Abstract

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Claims (237)

1. A compound having formula IIIB:

wherein:

X 9 is CH 2 or CF 2 ;

m is 0 to 4;

Ht 1 is a 5-membered heteroaromatic ring containing 1-4 heteroatoms selected from O, S, N, or NH;

x, q, and z is independently 0-5;

X—R x is H or unsubstituted alkyl;

Z—R z is halo, C 1 -C 8 aliphatic, OR 6 , SO 2 R 6 , CF 3 , or two occurrences of Z—R z taken together with the atom(s) to which they are bound form a ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur;

L is CHR L ;

R L is —OR′ or —N(R′) 2 ;

Ar is phenyl or a six-membered heteroaromatic ring;

R′ is independently selected from hydrogen or an optionally substituted group selected from a C 1- C 8 aliphatic group, or a 3-8-membered saturated, partially unsaturated, or fully unsaturated monocyclic ring having 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two occurrences of R′ are taken together with the atom(s) to which they are bound to form an optionally substituted 3-12 membered saturated, partially unsaturated, or fully unsaturated monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and

R 6 is H or aliphatic.

2. The compound according to claim 1 , wherein two R′ in N(R′) 2 taken together with the nitrogen atom, form an optionally substituted 3-7 membered heterocyclic ring containing up to 4 heteroatoms selected from O, N, or S.

3. The compound according to claim 1 , wherein m is 0.

4. The compound according to claim 1 , wherein Ht 1 is a thiazolyl ring, wherein Ht is optionally substituted with up to three substituents.

5. The compound according to claim 1 , wherein X 9 is CH 2 .

6. The compound according to claim 1 , wherein X 9 is CF 2 .

7. The compound according to claim 1 , wherein L is —CH 2 —.

8. The compound according to claim 1 , wherein L is —CH—R L , wherein R L is —OH, —NHR D , or NR AA R BB ; wherein

each of R AA , R BB , and R D is independently hydrogen, C1-C6 aliphatic, C3-C7 cycloalkyl, (C3-C7-cycloalkyl)-C1-C6 aliphatic, (C3-C7-cycloalkenyl)-C1-C6-aliphatic, 3-7-membered heterocyclyl-, (3-7-membered heterocyclyl)-C1-C6-aliphatic, 3-6-membered heteroaryl, (3-6-membered heteroaryl)-C1-C6 aliphatic, wherein said aliphatic, cycloalkyl, cycloalkenyl, heterocyclyl, or heteroaryl is optionally substituted with up to three substituents selected from OH, —O(C 1-4 aliphatic), or (C1-C4 aliphatic) p -Y; wherein

p is 0 or 1;

Y is OR or NHC(O)R;

R is hydrogen or C 1-4 aliphatic; or

R AA and R BB , taken together with the nitrogen atom, is a 3-7 membered heterocyclic ring containing up to 4 heteroatoms selected from O, wherein said ring is optionally substituted with up to 2 substituents selected from oxo or (C1-C4 aliphatic) p -Y; and

wherein up to two methylene groups in any said aliphatic above are optionally and independently replaced with O, C(O), or NH.

9. The compound according to claim 8 , wherein R D is hydrogen.

10. The compound according to claim 8 , wherein R D is optionally substituted C1-C6 aliphatic.

11. The compound according to claim 8 , wherein R D is selected from C1-C6 alkyl, optionally substituted with up two substituents selected from OH, O—(C1-C4 alkyl), acetamido, NH 2 , NH(C1-C4 alkyl), or N(C1-C4 alkyl) 2 .

12. The compound according to claim 8 , wherein R D is selected from an optionally substituted C3-C6 cycloalkyl or cycloalkenyl ring, or (C3-C6 cycloalkyl or cycloalkenyl ring)-C1-C6 aliphatic.

13. The compound according to claim 8 , wherein R D is selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenylethyl or cyclohexylmethyl.

14. The compound according to claim 8 , wherein R D is selected from optionally substituted 3-7 membered heterocyclyl or (3-7 membered heterocyclyl)-C1-C6 aliphatic, wherein said heterocyclyl contains up to 2 heteroatoms selected from O, S, or N.

15. The compound according to claim 8 , wherein R D is selected from (N-methyl-pyrrolidin-2-yl)-ethyl, pyrrolidin-1-yl-ethyl, tetrahydrofuran-2-yl-methyl, morpholin-4-yl-ethyl, or morpholin-4-yl-propyl.

16. The compound according to claim 8 , wherein R D is selected from optionally substitued 5-6 membered heteroaryl or (5-6-membered heteroaryl)-C1-C6 aliphatic, wherein said heteroaryl contains up to 2 heteroatoms selected from O, S, or N.

17. The compound according to claim 8 , wherein R D is selected from imidazolylpropyl, furanylmethyl, or pyridinylethyl.

18. The compound according to claim 8 , wherein R D is selected from C 1-4 alkyl optionally substituted with —OH, —O(C 1-4 alkyl), NH(C 1-4 alkyl), or N(C 1-4 alkyl) 2 .

19. The compound according to claim 8 , wherein R D is selected from C 1-4 alkyl optionally substituted with 5-6 membered heterocyclic ring containing up to 2 heteroatoms selected from O, N, or S, wherein said ring is optionally substituted with up to 2 substituents selected from oxo, (C 1-4 aliphatic), (C 1-4 aliphatic)-Y, wherein Y is halo, —OH, or —O(C 1-4 alkyl).

20. The compound according to claim 8 , wherein R D is selected from C 1-6 alkyl optionally substituted with —OH or —O(C 1-4 alkyl).

21. The compound according to claim 8 , wherein one of R AA and R BB is C1-C4 alkyl, and the other of R AA and R BB is selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, (C3-C6 cycloalkyl)-C1-C4 alkyl, wherein said alkyl, alkenyl, or cycloalkenyl has up to 2 substituents selected from OH or —O(C1-C4 alkyl).

22. The compound according to claim 8 , wherein R AA and R BB , taken together with the nitrogen atom, forms a ring selected from pyrrolidinyl, piperidinyl, or morpholinyl, wherein said ring is optionally substituted with up to two substituents selected from hydroxy, C1-C4 alkyl, C2-C4 alkenyl, COOH, acetoxy, acetyl, hydroxymethyl, methoxymethyl, hydroxyethyl, methoxyethyl, allyl, ethylenedioxy, or C(O)NH 2 .

23. The compound according to claim 8 , wherein said compound has formula VB-3-i:

wherein X 9 is CH 2 or CF 2 ;

R AA and R BB are selected from hydrogen, C1-C6 alkyl, or —CH(C1-C6 alkyl)-CH 2 OH; or

R AA and R BB taken together form a pyrrolidinyl ring optionally substituted with (C1-C4 aliphatic) p -Y.

24. The compound according to claim 23 , wherein R AA and R BB taken together is 3-acetoxy -pyrrolidin-1-yl, 2-methoxymethyl-pyrrolidin-1-yl, 2-hydroxymethyl-pyrrolidin-1-yl, (2-carboxypyrrolidin -1-yl), pyrrolidin-1-yl, 2-aminocarbonyl-pyrrolidin-1-yl, or 3-hydroxy-pyrrolidin-1-yl.

25. The compound according to claim 23 , wherein R AA is hydrogen, and R BB is —CH(C1-C6 alkyl)-CH 2 OH.

26. The compound according to claim 25 , wherein said alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, or isobutyl.

27. The compound according to claim 25 , wherein said R BB is (R)—CH (C1-C6 alkyl)-CH 2 OH or R BB is (S)—CH(C1-C6 alkyl)-CH 2 OH.

28. A compound selected from the following table:

Cmpd #

Compound

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

29. A pharmaceutical composition comprising:

(i) a compound according to claim 1 ; and

(ii) a pharmaceutically acceptable carrier.

30. The composition of claim 29 , further comprising an additional agent selected from a mucolytic agent, bronchodialator, an anti-biotic, an anti-infective agent, an anti-inflammatory agent, CFTR corrector, or a nutritional agent.

31. The compound according to claim 1 , wherein XR X is hydrogen.

32. The compound according to claim 1 , where in ZR Z is selected from halo, CF 3 , OCF 3 , C1-C4 alkoxy, methylenedioxy, or difluoromethylenedioxy.

33. The compound according to claim 1 , wherein z is 1-3.

34. The compound according to claim 1 , wherein the compound is

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2006
From: RUAH, SARA HADIDA; GROOTENHUIS, PETER; MILLER, MARK; HAMILTON, MATTHEW
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 017837/0918 →
Continuity (3)
Provisional Application 60540564 · Jan 30, 2004
Provisional Application 60603503 · Aug 20, 2004
Related Publication 20080176899A1 · Jul 24, 2008